Aster DM Healthcare Ratios

Aster DM Healthcare Ltd Ratios

The Aster DM Healthcare Ltd Ratios page provides a complete fundamental analysis of Aster DM Healthcare Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Aster DM Healthcare Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Aster DM Healthcare Ltd (NSE: ASTERDM, BSE: 540975) is currently trading at ₹635.15, with a market capitalization of ₹324.42B. As a major player in the Health services sector and Hospital/Nursing management industry, Aster DM Healthcare Ltd remains a key stock for fundamental analysis using Aster DM Healthcare Ltd Ratios.

Aster DM Healthcare Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Aster DM Healthcare Ltd P/E ratio currently stands at 4.49, making it one of the most tracked metrics in Aster DM Healthcare Ltd Ratios.

Historically, the Aster DM Healthcare Ltd P/E ratio has shown strong fluctuations:

• 2024: 4.49
• 2023: 157.61
• 2022: 28.30
• 2021: 18.63
• 2020: 46.25

The decline in Aster DM Healthcare Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Aster DM Healthcare Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 7.05.

Historical P/B trend:

• 2024: 7.05
• 2023: 4.47
• 2022: 2.70
• 2021: 2.48

Aster DM Healthcare Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Aster DM Healthcare Ltd P/S ratio currently stands at 5.84, an important part of Aster DM Healthcare Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 5.84
• 2023: 5.51
• 2022: 4.02
• 2021: 0.96

The rising Aster DM Healthcare Ltd P/S ratio indicates improved revenue valuation by investors.

Aster DM Healthcare Ltd Price to Cash Flow Ratio (P/CF)

The Aster DM Healthcare Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 55.86.

Historical Aster DM Healthcare Ltd Price to Cash Flow Ratio:

• 2024: 55.86
• 2023: 0
• 2022: 7.13
• 2021: 8.21
• 2020: 4.85

The rising Aster DM Healthcare Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Aster DM Healthcare Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Aster DM Healthcare Ltd EV currently stands at ₹250.32B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 250.32B
• 2023: 221.14B
• 2022: 176.97B
• 2021: 148.49B

Aster DM Healthcare Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Aster DM Healthcare Ltd EV/EBITDA ratio is currently 32.07, a key metric in Aster DM Healthcare Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 32.07
• 2023: 37.21
• 2022: 38.42
• 2021: 9.65

Stable Aster DM Healthcare Ltd EV/EBITDA indicates balanced valuation.

Aster DM Healthcare Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Aster DM Healthcare Ltd D/E ratio is currently 0.59, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.59
• 2023: 0.30
• 2022: 1.28
• 2021: 1.24

Aster DM Healthcare Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Aster DM Healthcare Ltd ROE currently stands at 7.68%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 7.68
• 2023: 3.98
• 2022: 3.32
• 2021: 14.36

Declining ROE indicates pressure on profitability.

Aster DM Healthcare Ltd Ratios Analysis Summary

The Aster DM Healthcare Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Aster DM Healthcare Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Aster DM Healthcare Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.